<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01113333</url>
  </required_header>
  <id_info>
    <org_study_id>TDU10820</org_study_id>
    <secondary_id>2009-017502-36</secondary_id>
    <secondary_id>U1111-1116-5630</secondary_id>
    <nct_id>NCT01113333</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of SAR113945 Following Intra-articular Administration in Patients With Knee Osteoarthritis</brief_title>
  <official_title>A Double Blind, Placebo Controlled Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the IKK Inhibitor, SAR113945, Following Intra-articular Administration in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

        -  Assess the safety and tolerability of single intra-articular doses of SAR113945 in
           patients with knee osteoarthritis.

      Secondary Objective:

        -  Assess systemic exposure of SAR113945 following intra-articular delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration per subject ranges from 4 to 20 weeks broken down as follows:

        -  screening within 4 weeks before dosing,

        -  follow-up of 4 weeks (28 days) after the single dose of study medication,

        -  prolonged by a maximum of 12 weeks if plasma PK level &gt; Limit Of Quantification (LOQ) at
           Day 28.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standard safety investigations (Physical examinations, 12 lead ECGs, vital signs (Blood pressure, heart rate, body temperature) and laboratory tests (hematology/coagulation, biochemistry, quantitative urinalysis))</measure>
    <time_frame>4 weeks up to a maximum of 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Examination of skin/soft tissue of injected knee</measure>
    <time_frame>4 weeks up to a maximum of 12 weeks</time_frame>
    <description>Any reaction is classified as erythema, oedema, pain, papulae, haematoma and graded none, mild, moderate or severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Examination of knee joint of injected knee</measure>
    <time_frame>4 weeks up to a maximum of 12 weeks</time_frame>
    <description>Any reaction is classified as effusion/worsening of effusion, warm and pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters for SAR113945 and potential metabolites(s) from plasma concentration (i.e. AUC, Cmax, tmax, t1/2)</measure>
    <time_frame>4 weeks up to a maximum of 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameters (WOMAC Index, biomarkers relating to inflammation and cartilage/bone turnover)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>SAR113945</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR113945, single dose according to dose escalation design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% saline solution, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form:injection
Route of administration: intra-articular</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR113945</intervention_name>
    <description>Pharmaceutical form:injection
Route of administration: intra-articular</description>
    <arm_group_label>SAR113945</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male patients or female patients of non child-bearing potential, aged at least 40
             years with primary knee osteoarthritis having:

               -  X-ray or Magnetic Resonance Imaging (MRI) evidence for Kellgren Lawrence Grades
                  II./III joint space narrowing and osteophyte formation,

               -  Western Ontario MacMaster (WOMAC) score â‰¦ 72,

               -  American College of Rheumatology (ACR) Clinical and Radiographic criteria for
                  osteoarthritis.

        Exclusion criteria:

          -  Any uncontrolled, chronic condition or laboratory finding which, in the opinion of the
             Principal Investigator, could potentially put the patient at increased risk.

          -  Secondary osteoarthritis.

          -  Moderate/severe renal impairment.

          -  Underlying hepatobiliary disease and/or elevated Alanine Aminotransferase (ALT) &gt; 3
             Upper Limit of Normal range.

          -  Intra-articular injection within 3 months.

          -  Presence of local skin abnormality at the affected knee joint.

          -  Unable to be maintained for at least 2 weeks prior to entry into study on paracetamol
             or metamizole as analgesic.

          -  Any Investigational Product within 3 months.

          -  Any patient unlikely to comply with the requirements of the study.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 276001</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>April 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2010</study_first_posted>
  <last_update_submitted>March 22, 2011</last_update_submitted>
  <last_update_submitted_qc>March 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Trial Transparency Team</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

